Introduction
============

Primary hyperparathyroidism (PHPT) is a common disorder characterized by incomplete regulation and excessive secretion of parathyroid hormone (PTH) from one or more of the parathyroid glands.[@b1-vhrm-13-225] This condition is easily diagnosed by the occurrence of an inappropriately high serum PTH level, along with hypercalcemia. However, normocalcemia in the presence of an increased serum PTH level may be due to normocalcemic primary hyperparathyroidism (NPHPT). In such cases, it is necessary to exclude secondary causes of PTH elevation, such as vitamin D deficiency, renal failure, and use of thiazide diuretic or lithium, among others.[@b1-vhrm-13-225]--[@b3-vhrm-13-225] NPHPT may not be an indolent disease because a high prevalence of nephrolithiasis has been shown,[@b4-vhrm-13-225] and some studies have suggested an increased cardiovascular risk.[@b3-vhrm-13-225]--[@b5-vhrm-13-225]

The prevalence of NPHPT is not well defined due to the different exclusion criteria for secondary causes used in studies. A recent population-based research in Italy evaluated the prevalence of NPHPT and reported a rate of 0.58% in females and 0.44% in males.[@b6-vhrm-13-225] A Brazilian study on 156 females from an osteoporosis data bank in an Endocrinology and Bone Metabolism reference center found 14 patients with NPHPT, representing a prevalence of 8.9% of the population studied.[@b7-vhrm-13-225]

An increase in cardiovascular morbidity and mortality is described in classic symptomatic PHPT.[@b8-vhrm-13-225] However, this remains controversial in mild disease, in which the serum calcium level is increased to 1 mg/dL of the upper limit of normal,[@b9-vhrm-13-225] although there is evidence of more subtle cardiovascular changes, such as increased vascular stiffness, among others.[@b8-vhrm-13-225]

Because the diagnosis of PHPT has been previously given with more subtle clinical findings, the investigation of cardiovascular manifestations of the disease has recently turned to less obvious clinical abnormalities.[@b8-vhrm-13-225],[@b10-vhrm-13-225] The coronary calcium score (CCS) is a quantitative index of the total coronary artery calcium detected by a computed tomography (CT) scan without the use of contrast media.[@b11-vhrm-13-225] A high CCS indicates an increased cardiovascular risk in both young and elderly individuals, with a high positive predictive value for cardiovascular disease in all age groups.[@b12-vhrm-13-225]

According to the Fourth International Workshop on Asymptomatic PHPT, there is a lack of prospective data on cardiovascular outcomes in asymptomatic PHPT. Moreover, the data on the extent and nature of cardiovascular involvement in patients with mild disease are limited. The carotid seems to be more affected than the heart. Routine cardiovascular analysis of these patients is still not recommended and therefore should not be considered in the decision for surgical treatment.[@b13-vhrm-13-225]

Study population and methods
============================

Thirteen female NPHPT patients with no preexisting clinical coronary artery disease (CAD) and a control group of 16 females matched for age were evaluated. NPHPT was defined as a serum PTH level above the upper limit of normal, with a normal albumin-adjusted serum calcium level, excluding the following: disorders associated with secondary hyperparathyroidism such as kidney failure (glomerular filtration rate \[GFR\] \<60 mL/min) and vitamin D deficiency (serum 25-OH vitamin D \<20 ng/mL, use of thiazide diuretic or lithium, and presence of gastrointestinal disorders associated with calcium malabsorption.

The study protocol was approved by the ethics in research committee of the University of Pernambuco. All patients provided written informed consent.

The blood pressure (BP) of the patients was measured using an Omron HEM-742INT monitor. The measurements were carried out according to the guidelines and recommendations of the European Society of Hypertension and the European Society of Cardiology.[@b14-vhrm-13-225]

Dry biochemical analysis (Johnson & Johnson) was carried out after 12 h of fasting, and the glycated hemoglobin (HbA1c) concentrations were determined by using a turbidimetric immunoassay (Roche Diagnostics). The serum PTH levels were measured by immunochemiluminescence (Architect; Abbott), and the serum 25-OH vitamin D levels were measured by competitive electrochemiluminescence immunoassay (Liaison; DiaSorin), with inter- and intra-assay coefficients of variation of 8%--15% and 8%--13%, respectively; the limit of detection was 2 ng/mL.[@b15-vhrm-13-225]

The Agatston calcium score was determined from the product of the total area of calcium derived by a factor of maximum density.[@b16-vhrm-13-225]--[@b18-vhrm-13-225] A Philips Brilliance CT scanner with 10 channels was used to measure the coronary calcification area. It was divided into the following: CCS =0; negative, which indicates a low probability of CAD and future cardiovascular events; and altered CCS, with value ≥0.[@b16-vhrm-13-225]--[@b18-vhrm-13-225]

Statistical analysis
--------------------

The categorical data were expressed as absolute and relative frequencies and presented in frequency tables. The numerical data were summarized as mean values and standard deviations. In comparing the clinical characteristics between different groups of patients with normal and abnormal CCS values, Pearson's chi-square test was applied when the independent variable was categorical, and Student's *t*-test when the variable was quantitative. The presence of an association between the CCS and the clinical and laboratory variables was estimated by using the prevalence ratios, along with their confidence intervals; the association was adjusted for possible confounders by multivariate logistic regression. The level of significance in the analysis of associations was set at 5% (*p*\<0.05).

Results
=======

Of the 13 patients with NPHPT, 4 (30.77%) had a CCS value \>0, as described below.

The first case was a 66-year-old hypertensive patient with a body mass index (BMI) of 31.71 kg/m^2^, abdominal circumference (AC) of 94 cm, serum 25-OH vitamin D of 44 ng/mL, and PTH of 93 pg/mL, with a family history of early CAD and a CCS of 273.

The second case, a 65-year-old hypertensive patient, had a BMI of 35.17 kg/m^2^, AC of 104 cm, serum 25-OH vitamin D of 34.4 ng/mL, and PTH of 92 pg/mL. The patient was taking vitamin D and calcium supplements, was on statin therapy, and had a family history of early CAD; the CCS was 41.4.

The third case was a 68-year-old diabetic and hypertensive patient with a BMI of 24.03 kg/m^2^, AC of 84 cm, serum 25-OH vitamin D of 25.2 ng/mL, and PTH of 192 pg/mL; this patient was on statin therapy and had a CCS of 309.8.

The fourth case was 71 years old, with a BMI of 26.03 kg/m^2^, AC of 86 cm, serum 25-OH vitamin D of 21 ng/mL, and PTH of 103 pg/mL; the patient was on statin and had a CCS of 30.

The patients with NPHPT had an average age of 65 (±7.71) years, similarly to the members of the control group, whose average age was 61 (±7.65) years (*p*=0.165). A statistically significant difference in BMI (26.97 kg/m^2^ vs 31.53 kg/m^2^, respectively; *p*=0.044) was found between the groups.

Regarding the laboratory findings, differences between the groups were observed in the levels of fasting plasma glucose (92±13.68 mg/dL vs 102.58±14.66 mg/dL, respectively; *p*=0.056), HbA1c (5.59±0.34% vs 6.62±0.58%, respectively; *p*=0.000), and total cholesterol (TC) (188.07±32.99 mg/dL vs 220.64±59.14 mg/dL, respectively; *p*=0.088).

A significant difference in the diagnosis of diabetes mellitus was observed between the groups, with only 1 (7.69%) patient among the cases having such diagnosis compared with 6 (37.5%) in the control group (*p*=0.062). There was also a significant difference in vitamin D supplementation between the groups (53.85% vs 12.5%, respectively; *p*=0.017) ([Table 1](#t1-vhrm-13-225){ref-type="table"}).

In the control group, 10 (62.5%) patients were found to have altered CCS. The initial analysis showed no association between presence of NPHPT and altered CCS (odds ratio \[OR\]: 0.27; 95% confidence interval \[CI\]: 0.05--1.26; *p*=0.095) ([Table 2](#t2-vhrm-13-225){ref-type="table"}).

After adjusting for the covariates such as BMI, HbA1c, and TC levels, and possible confounding factors in the association between NPHPT and altered CCS, no significant difference was found in the case group with altered CCS (adjusted OR: 1.64; 95% CI: 0.1--26.43; *p*=0.726) ([Table 3](#t3-vhrm-13-225){ref-type="table"}).

Discussion
==========

This study investigated the role of CCS in patients with NPHPT. No previous research has specifically investigated this association. In fact, the clinical conditions of NPHPT are not yet well characterized, and prospective data on the cardiovascular risk in this group of patients are lacking. In the current work, we measured the CCS, which has been recognized as a good predictor of cardiovascular disease in asymptomatic patients.[@b19-vhrm-13-225]

The initial analysis showed no association between CCS \>0 and diagnosis of NPHPT (OR: 0.27; 95% CI: 0.05--1.26; *p*=0.095). By using a similar protocol but in a different population, Kepez et al[@b9-vhrm-13-225] evaluated 31 patients with mild PHPT, which was defined as an increase in serum calcium level of up to 1 mg/dL above the upper limit of normal, compared with 19 controls; the CCS of the patients was measured by using CT. The authors did not find a positive association between asymptomatic PHPT and coronary calcification.[@b9-vhrm-13-225]

A population-based study that evaluated metabolic abnormalities in 30 patients with NPHPT compared with 30 controls found significantly higher levels of blood glucose and triglycerides, as well as a higher mean BMI and lower high-density lipoprotein (HDL) cholesterol levels, in the group with increased PTH, suggesting metabolic changes in NPHPT associated with cardiovascular risk.[@b20-vhrm-13-225]

In the current study, however, more metabolic changes were observed in the control group, and although the groups were matched for age, the control group had a significantly higher mean BMI (31.53 kg/m^2^ vs 26.97 kg/m^2^; *p*=0.044) and mean HbA1c level (6.62% vs 5.59%; *p*=0.000) and showed a trend toward higher mean fasting plasma glucose (102.58 mg/dL vs 92 mg/dL; *p*=0.056) and TC (220.64 mg/dL vs 188.07 mg/dL; *p*=0.088) levels. In addition to the differences in clinical and laboratory results, the diagnosis of diabetes mellitus also differed between the groups, with only 1 (7.69%) patient having such diagnosis in the case group compared with 6 (37.5%) in the control group (*p*=0.062), findings which may have been potential confounders.

The current work found no difference between the case and control groups in either the diagnosis of hypertension or changes in BP levels. In contrast, a recent retrospective study that compared the systolic and diastolic BP levels between a group of 11 patients with NPHPT and 296 control patients found that patients with high PTH and normal calcium levels had higher BP levels than those without NPHPT.[@b21-vhrm-13-225] The results of the current study may have been influenced by the fact that the control group had a higher BMI than the case group, given that it is well established in the literature that hypertension is correlated with excess weight.[@b22-vhrm-13-225]

Strength vs limitations
-----------------------

This is the first study to verify the association between NPHPT and changes in CCS. However, this research had a small sample size, and the control group had higher rates of known cardiovascular risk factors.

Conclusion
==========

No association was found between the CCS and NPHPT.
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###### 

Baseline characteristics of study parameters

  Covariates                                                                              NPHPT            Controls                  *p*-value
  --------------------------------------------------------------------------------------- ---------------- ------------------------- -----------
  Age, years, mean ± SD                                                                   65.15±7.71       61.06±7.65                0.165
  Body mass index, kg/m^2^, mean ± SD                                                     26.97±5.14       31.53±6.25                0.044
  Abdominal circumference, cm, mean ± SD                                                  93.84±11.15      100.93±12.97              0.131
  Glycemia, mg/dL, mean ± SD                                                              92±13.68         102.58±14.66              0.056
  Glycated hemoglobin, %, mean ± SD                                                       5.59±0.34        6.62±0.58                 0.000
  Altered blood pressure, mmHg, n (%)                                                     8 (61.54)        11 (68.75)                0.684
  Total cholesterol, mg/dL, mean ± SD                                                     188.07±32.99     220.64±59.14              0.088
  HDL-cholesterol, mg/dL, mean ± SD                                                       50.38±15.46      49.45±12.60               0.860
  LDL-cholesterol, mg/dL, mean ± SD                                                       109.56±32.4      134.73±53.07              0.146
  Triglycerides, mg/dL, median (P25--P75)[\*\*](#tfn2-vhrm-13-225){ref-type="table-fn"}   146 (114--156)   152.49 (112.34--237.15)   0.219
  Corrected calcium, mg/dL, mean ± SD[\*](#tfn1-vhrm-13-225){ref-type="table-fn"}         9.28±1.05        8.28±0.45                 0.002
  Glomerular filtration rate, mL/min, mean ± SD                                           89.87±19.66      98.88±20.66               0.243
  25-OH vitamin D, ng/mL, mean ± SD                                                       35.32±8.42       26.11±8.94                0.008
  PTH, pg/mL, mean ± SD                                                                   100.58±29.83     30.26±12.00               0.000
  **Comorbidities**, n (%)                                                                11 (84.62)       15 (93.75)                0.422
   Smoking, n (%)                                                                         0                2 (12.5%)                 0.186
   Family history of early CAD, n (%)                                                     2 (15.38)        0                         0.104
   Dyslipidemia, n (%)                                                                    9 (69.23)        13 (81.25)                0.452
   Hypertension, n (%)                                                                    8 (61.54)        11 (68.75)                0.684
   Diabetes mellitus, n (%)                                                               1 (7.69)         6 (37.5)                  0.062
  **Medications**                                                                                                                    
   Vitamin D replacements, n (%)                                                          7 (53.85)        2 (12.5)                  0.017
   Calcium replacement, n (%)                                                             1 (7.69)         0                         0.259
   Bisphosphonate, n (%)                                                                  2 (15.38)        0                         0.104
   Oral hypoglycemic, n (%)                                                               0                6 (37.5)                  0.013
   Insulin, n (%)                                                                         0                1 (6.25)                  0.359
   Statin, n (%)                                                                          7 (53.85)        6 (46.15)                 0.379
   Angiotensin-converting enzyme inhibitor, n (%)                                         3 (23.08)        4 (25)                    0.904
   Angiotensin receptor blocker, n (%)                                                    4 (36.36)        7 (63.64)                 0.513
   Calcium channel blocker, n (%)                                                         2 (15.38)        3 (18.75)                 0.811
   Platelet antiaggregant, n (%)                                                          2 (15.38)        0                         0.104

**Notes:**

Mean ± SD: Student's *t*-test;

Kruskal--Wallis test. Median, P50.

**Abbreviations:** CAD, coronary artery disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NPHPT, normocalcemic primary hyperparathyroidism; P25/P50/P75, 25th, 50th, and 75th percentiles, respectively; PTH, parathyroid hormone; SD, standard deviation.

###### 

Association between coronary calcium score and NPHPT

  Factor   n (%)        OR (95% CI)   *p*-value           
  -------- ------------ ------------- ------------------- -------
  NPHPT                                                   
  No       10 (62.5)    6 (37.5)      Reference           NA
  Yes      4 (30.77)    9 (69.23)     0.27 (0.05--1.26)   0.095
  Total    14 (48.28)   15 (51.72)    NA                  NA

**Abbreviations:** CCS, coronary calcium score; CI, confidence interval; NPHPT, normocalcemic primary hyperparathyroidism; NA, not available; OR, odds ratio; PTH, parathyroid hormone.

###### 

Association between coronary calcium score and the condition of NPHPT adjusted for potential confounders[\*](#tfn5-vhrm-13-225){ref-type="table-fn"}

  Calcium score   OR          *p*-value   OR~adjusted~        *p*-value
  --------------- ----------- ----------- ------------------- -----------
  NPHPT                                                       
  No              Reference   NA          Reference           NA
  Yes             0.27        0.096       1.64 (0.1--26.43)   0.726

**Note:**

Adjusted for covariates such as body mass index, glycated hemoglobin, and total cholesterol.

**Abbreviations:** NA, not available; NPHPT, normocalcemic primary hyperparathyroidism; OR, odds ratio.
